News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Invitation to investor meeting 5th April 2023, 2:00 pm (CET)

28 March 2023

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer

8 March 2023

Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio Copy

23 January 2023

R&D Day Presentation, 07.12.2022

7 December 2022

Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022

5 December 2022

Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland

28 November 2022

Events & Presentations

EFMC – International Symposium on Medicinal Chemistry – Ljubljana 02-06.09.2018

17 September 2018

ERS International Congress 2018 – Paris, France 15-19.09.2018

14 September 2018

54th International Conference on Medicinal Chemistry, Strasbourg, France – July 4-6, 2018.

17 July 2018

ATS 2018, 18 – 23 May, San Diego, USA

21 May 2018

ESMO Immuno Oncology Congress Geneva – December 7-10

1 December 2017

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2017

1 October 2017